Department of Medical Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
J Clin Pathol. 2013 Jul;66(7):607-12. doi: 10.1136/jclinpath-2012-201088. Epub 2013 Mar 13.
Poly(ADP-ribose)polymerase (PARP) inhibitors represent a new class of promising drugs in anticancer therapy.
To evaluate PARP expression in testicular germ cell tumours (GCTs) and to correlate expression patterns with clinicopathological variables.
In this translational study, tumour specimens from 124 patients with GCTs (114 patients with testicular primary tumours and 10 with extragonadal GCTs) were identified. PARP expression was detected by immunohistochemistry using monoclonal antibodies, scored by the multiplicative quickscore (QS) method and compared to PARP expression in normal testicular tissue.
We observed higher expression of PARP in testicular tumours compared to normal testicular tissue (mean QS=10.04 vs 3.31, p<0.0000001). Mean QS±SD for each histological subtype was as follows: intratubular germ cell neoplasia unclassified (IGCNU)=18.00±0.00, embryonal carcinoma=9.62±5.64, seminoma=9.74±6.51, yolk sac tumour=7.8±7.20, teratoma=5.87±5.34, and choriocarcinoma=4.50±8.33. The PARP overexpression (QS>9) was most often detected in IGCNU (100% of specimen with PARP overexpression), seminona (52.6%), embryonal carcinoma (47.0%), yolk sac tumour (33.3%), teratoma (26.7%) and choriocarcinoma (25.0%), compared to 1.9% of normal testicular tissue specimens. There was no association between PARP expression and clinical variables.
In this pilot study, we showed for the first time, that PARP is overexpressed in testicular germ cell tumours compared to normal testis.
聚（ADP-核糖）聚合酶（PARP）抑制剂是癌症治疗中一类有前途的新药。
评估 PARP 在睾丸生殖细胞肿瘤（GCT）中的表达，并将表达模式与临床病理变量相关联。
在这项转化研究中，鉴定了 124 例 GCT 患者（114 例睾丸原发性肿瘤患者和 10 例性腺外 GCT 患者）的肿瘤标本。使用单克隆抗体通过免疫组织化学检测 PARP 表达，通过乘法快速评分（QS）方法进行评分，并与正常睾丸组织中的 PARP 表达进行比较。
与正常睾丸组织相比，我们观察到睾丸肿瘤中 PARP 的表达更高（平均 QS=10.04 与 3.31，p<0.0000001）。每个组织学亚型的平均 QS±SD 如下：未分类的小管内生殖细胞肿瘤（IGCNU）=18.00±0.00，胚胎癌=9.62±5.64，精原细胞瘤=9.74±6.51，卵黄囊肿瘤=7.8±7.20，畸胎瘤=5.87±5.34，绒毛膜癌=4.50±8.33。PARP 过表达（QS>9）最常出现在 IGCNU（100%的 PARP 过表达标本）、精原细胞瘤（52.6%）、胚胎癌（47.0%）、卵黄囊肿瘤（33.3%）、畸胎瘤（26.7%）和绒毛膜癌（25.0%）中，而正常睾丸组织标本中为 1.9%。PARP 表达与临床变量之间没有关联。
在这项初步研究中，我们首次表明，PARP 在睾丸生殖细胞肿瘤中表达高于正常睾丸。
